Idorsia Ltd (IDRSF) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 1:30 PM EST
Company Participants
Srishti Gupta – CEO & Executive Director
Martine Clozel – Executive VP, Chief Scientific Officer & Head of Research
Conference Call Participants
Farhan Khan
Presentation
Farhan Khan
Hi. Good morning, everyone. My name is Farhan Khan, and I’m an associate with the Healthcare Investment Banking Group here at JPMorgan. It’s my great pleasure today to be introducing Idorsia. Presenting today is Idorsia’s CEO, Srishti Gupta. We also have key members of the leadership team, Arno Groenewoud, CFO; and Martine Clozel, who’s the Co-Founder, Chief Scientific Officer and Head of Research, will be joining for the Q&A panel.
After the presentation, we’ll have about 10 minutes for the Q&A. So please hold your questions until then. And with that, please join me in welcoming Srishti.
Srishti Gupta
CEO & Executive Director
Hi, everyone. Thank you for joining us. I’m Dr. Srishti Gupta, the CEO of Idorsia, and it is a pleasure to be here. It’s the first time I’m presenting at JPMorgan since becoming the CEO in July 2025. Prior to that, I was on the Board. I’ve been on the Board of Idorsia since May 2021. So today, I’ll share the highlights of 2025 with you as well as our strategy going forward for 2026.
So for those of you who don’t know us, we built on a proven foundation; the talent, The legacy, and the drug discovery engine of Actelion. And that’s the reason we have conviction in our strategy. The teams, the core science and the capabilities that created so much value in the past are the same ones that will be creating value in the future.
We are executing a focused and balanced approach to our strategy, which is to
